RSV Infection Clinical Trial
Official title:
Phase I, Single-centre, Randomised, Placebo-controlled, Double-blinded Study, With Single Ascending Dose and Multiple Dose at Maximum Tolerated Dose, Evaluating the Safety, Tolerability and Pharmacokinetics of ALX-0171, Administered by Pulmonary Inhalation, in Healthy Male Volunteers
ALX-0171 is a Nanobody directed against the human respiratory syncytial virus (RSV). The purpose of this first-in-man study is to determine the safety, tolerability and pharmacokinetics (PK) of ALX-0171 after single and multiple pulmonary administrations in healthy male volunteers.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Active, not recruiting |
NCT03698084 -
RESCEU: Defining the Burden of RSV Disease
|
||
| Recruiting |
NCT05550545 -
Infant RSV Infections and Health-related Quality of Life of Families
|
||
| Completed |
NCT05587478 -
A Study of EDP-323 in Healthy Subjects
|
Phase 1 | |
| Recruiting |
NCT06180993 -
Evaluation of the Effectiveness and Impact of Nirsevimab Administered as Routine Immunization
|
||
| Suspended |
NCT03909867 -
Emission Patterns of Respiratory Syncytial Virus
|
||
| Recruiting |
NCT06259487 -
Coordinated Vaccination Against RSV and Influenza in Patients With Chronic Heart Failure and Its Impact on Prognosis.
|
N/A | |
| Not yet recruiting |
NCT04144816 -
Predictors of Respiratory Syncytial Virus (RSV) Hospitalizations in Infants
|
||
| Completed |
NCT01090557 -
Exhaled Nitric Oxide in Respiratory Syncytial Virus (RSV) Bronchiolitis: a Pilot Study
|
N/A | |
| Terminated |
NCT01475305 -
Intranasal Challenge of Healthy Adults With Respiratory Syncytial Virus (RSV)
|
Phase 1 | |
| Not yet recruiting |
NCT05928507 -
FINDER® Instrument and FINDER® FLU A/B, RSV, SARS-CoV-2 Test Clinical Evaluation Protocol
|
||
| Completed |
NCT03062917 -
Nasal and Bronchial Absorption Sampling in RSV Bronchiolitis
|
N/A | |
| Completed |
NCT03691623 -
A Phase 2a Study to Evaluate EDP-938 in the Virus Challenge Model
|
Phase 2 | |
| Completed |
NCT03387137 -
Evaluating the Infectivity, Safety, and Immunogenicity of a Respiratory Syncytial Virus Vaccine (RSV 6120/∆NS2/1030s) in RSV-Seropositive Children and RSV-Seronegative Infants and Children
|
Phase 1 | |
| Completed |
NCT05070975 -
Severity of RSV Infections in Twins
|
||
| Recruiting |
NCT04938830 -
Clesrovimab (MK-1654) in Infants and Children at Increased Risk for Severe Respiratory Syncytial Virus (RSV) Disease (MK-1654-007)
|
Phase 3 | |
| Recruiting |
NCT05568706 -
A Study of EDP-938 in Non-hospitalized Adults With RSV Who Are at High Risk for Complications.
|
Phase 2 | |
| Completed |
NCT03755778 -
Drug-Drug Interaction Study Between EDP-938, Itraconazole, Rifampin, and Quinidine in Healthy Subjects
|
Phase 1 | |
| Recruiting |
NCT06170242 -
A Controlled Phase 2a Study to Evaluate the Efficacy of EDP-323 Against Respiratory Syncytial Virus Infection in a Virus Challenge Model
|
Phase 2 | |
| Completed |
NCT03750383 -
Drug-Drug Interaction Study Between EDP-938, Cyclosporine and Prednisone in Healthy Adult Subjects
|
Phase 1 | |
| Completed |
NCT05118386 -
Safety, Tolerability, and Pharmacokinetics of RSV Monoclonal Antibody RSM01 in Healthy Adults
|
Phase 1 |